Breaking News Instant updates and real-time market news.

MYL

Mylan

$41.65

-0.2 (-0.48%)

07:02
06/14/18
06/14
07:02
06/14/18
07:02

Mylan's stock may pull back through Q2, says RBC Capital

RBC Capital analyst Randall Stanicky kept his $42 price target and Sector Perform rating on Mylan following yesterday's FDA delay of generic Advair due to "minor deficiencies". The analyst notes that the company may be faced with worse than expressed business pressure and is also concerned that the Street may have over-modeled the Advair contribution, warning that the stock price may pull back through Q2. Stanicky says investors should await a better entry point opportunity on Mylan.

  • 13

    Nov

MYL Mylan
$41.65

-0.2 (-0.48%)

06/05/18
MZHO
06/05/18
NO CHANGE
Target $51
MZHO
Buy
Amgen estimates could drop 2% on Mylan approval, says Mizuho
The consensus 2018 earnings estimates for Amgen (AMGN) could move 2%, or 25c, after Mylan (MYL) won FDA approval for its biosimilar Neulasta, Mizuho analyst Salim Syed tells investors in a research note. The first channel at risk for Amgen is the 340B channel, which is a federal program that requires drug companies to provide drugs at heavily discounted prices, the analyst contends. Syed keeps a Buy rating on Amgen with a $200 price target.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
06/13/18
BMOC
06/13/18
NO CHANGE
Target $50
BMOC
Outperform
Mylan to have only a 'minor' delay to generic Advair approval, says BMO Capital
BMO Capital analyst Gary Nachman kept his Outperform rating and $50 price target on Mylan after today's post-market close disclosure by the FDA that the company's generic Advair had minor deficiencies. The analyst says that while this is not an "ideal scenario for this much-anticipated catalyst", he confirmed with the management that the FDA used the term "minor" in its letter. Nachman maintains that Mylan is still "very close" to generic Advair, adding that "there will only be a relatively minor delay to ultimate approval".
06/14/18
MZHO
06/14/18
NO CHANGE
Target $51
MZHO
Buy
Mylan to recover from 'modest' generic Advair delay, says Mizuho
Mizuho analyst Irina Koffler says Mylan's "modest" delay for generic Advair approval is unsurprising and unlikely to impact the company's 2018 guidance. She expects the stock to recover and reiterates a Buy rating on the name with a $51 price target.

TODAY'S FREE FLY STORIES

KOS

Kosmos

$9.45

-0.06 (-0.63%)

14:58
09/24/18
09/24
14:58
09/24/18
14:58
Hot Stocks
Breaking Hot Stocks news story on Kosmos »

First Reserve GP XIII…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWCH

Switch

$10.76

-0.3 (-2.71%)

14:58
09/24/18
09/24
14:58
09/24/18
14:58
Conference/Events
Switch management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

CGC

Canopy Growth

$52.68

2.92 (5.87%)

, CVSI

CV Sciences

$0.00

(0.00%)

14:55
09/24/18
09/24
14:55
09/24/18
14:55
Hot Stocks
NY Governor signs bill adding pain management as condition for medical marijuana »

New York Governor Andrew…

CGC

Canopy Growth

$52.68

2.92 (5.87%)

CVSI

CV Sciences

$0.00

(0.00%)

ACBFF

Aurora Cannabis

$0.00

(0.00%)

CRON

Cronos Group

$11.80

-0.71 (-5.68%)

TLRY

Tilray

$105.00

-18.155 (-14.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

SBUX

Starbucks

$56.88

-0.52 (-0.91%)

14:50
09/24/18
09/24
14:50
09/24/18
14:50
Periodicals
Starbucks plans 'significant changes' to company structure, Bloomberg says »

Starbucks'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

RRGB

Red Robin

$38.65

-0.55 (-1.40%)

14:50
09/24/18
09/24
14:50
09/24/18
14:50
Conference/Events
Red Robin management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ASNA

Ascena Retail

$3.94

-0.29 (-6.86%)

14:49
09/24/18
09/24
14:49
09/24/18
14:49
Options
Ascena Retail options imply 24.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AMRN

Amarin

$11.13

8.13 (271.00%)

, SNY

Sanofi

$43.33

-0.28 (-0.64%)

14:48
09/24/18
09/24
14:48
09/24/18
14:48
Hot Stocks
Amarin CEO says Vascepa 'more analogous' to statins than PCSK9 inhibitors »

Amarin CEO John Thero…

AMRN

Amarin

$11.13

8.13 (271.00%)

SNY

Sanofi

$43.33

-0.28 (-0.64%)

REGN

Regeneron

$388.88

-1.67 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

TRXC

TransEnterix

$6.70

0.27 (4.20%)

14:45
09/24/18
09/24
14:45
09/24/18
14:45
Options
TransEnterix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 27

    Nov

SPPI

Spectrum

$17.18

-4.19 (-19.61%)

14:44
09/24/18
09/24
14:44
09/24/18
14:44
Hot Stocks
Spectrum drops over 20% after releasing poziotinib data from Phase 2 study »

Shares of Spectrum are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

JNJ

Johnson & Johnson

$140.67

-2.18 (-1.53%)

14:43
09/24/18
09/24
14:43
09/24/18
14:43
Periodicals
J&J talc cancer case in California ends in mistrial, Bloomberg reports »

Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

VSTM

Verastem

$8.98

0.31 (3.58%)

14:39
09/24/18
09/24
14:39
09/24/18
14:39
Hot Stocks
Verastem's Duvelisib approved by FDA »

Duvelisib capsules for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

VSTM

Verastem

$8.98

0.31 (3.58%)

14:38
09/24/18
09/24
14:38
09/24/18
14:38
Hot Stocks
Breaking Hot Stocks news story on Verastem »

Verastem trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

P

Pandora

$9.07

-0.01 (-0.11%)

14:30
09/24/18
09/24
14:30
09/24/18
14:30
Options
Heavy trading in Pandora Monday »

Heavy trading in Pandora…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GOOG

Alphabet

$1,176.08

9.87 (0.85%)

, GOOGL

Alphabet Class A

$1,183.18

10.96 (0.93%)

14:28
09/24/18
09/24
14:28
09/24/18
14:28
Periodicals
Google to bring Google Lens to Image search results, Engadget says »

According to Engadget,…

GOOG

Alphabet

$1,176.08

9.87 (0.85%)

GOOGL

Alphabet Class A

$1,183.18

10.96 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

VIAB

Viacom

$32.44

0.08 (0.25%)

14:25
09/24/18
09/24
14:25
09/24/18
14:25
Options
Viacom call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
09/24/18
09/24
14:25
09/24/18
14:25
General news
FOMC begins its 2-day meeting Tuesday, with the announcement due Wednesday at 14 ET »

FOMC begins its 2-day…

ESRX

Express Scripts

$94.41

-0.2 (-0.21%)

, GILD

Gilead

$75.68

0.17 (0.23%)

14:20
09/24/18
09/24
14:20
09/24/18
14:20
Hot Stocks
Express Scripts calls Gilead action 'step in the right direction' »

Express Scripts (ESRX)…

ESRX

Express Scripts

$94.41

-0.2 (-0.21%)

GILD

Gilead

$75.68

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/24/18
09/24
14:17
09/24/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/24/18
09/24
14:16
09/24/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,177.62

11.41 (0.98%)

, GOOGL

Alphabet Class A

$1,184.38

12.16 (1.04%)

14:13
09/24/18
09/24
14:13
09/24/18
14:13
Hot Stocks
Google launches 'major update' Discover for Search »

Google said in a blog…

GOOG

Alphabet

$1,177.62

11.41 (0.98%)

GOOGL

Alphabet Class A

$1,184.38

12.16 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

14:10
09/24/18
09/24
14:10
09/24/18
14:10
General news
U.S. equities stabilized above lows after the Rosengren rout »

U.S. equities stabilized…

KORS

Michael Kors

$67.16

-5.51 (-7.58%)

14:09
09/24/18
09/24
14:09
09/24/18
14:09
Recommendations
Michael Kors analyst commentary  »

Versace not seen by many…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$140.70

-2.15 (-1.51%)

, BSX

Boston Scientific

$38.33

0.57 (1.51%)

14:05
09/24/18
09/24
14:05
09/24/18
14:05
Periodicals
J&J may be interested in Boston Scientific, Edwards Lifesciences, Barron's says »

According to an earlier…

JNJ

Johnson & Johnson

$140.70

-2.15 (-1.51%)

BSX

Boston Scientific

$38.33

0.57 (1.51%)

EW

Edwards Lifesciences

$165.13

11.42 (7.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

  • 16

    Oct

  • 28

    Oct

VKTX

Viking Therapeutics

$18.77

0.555 (3.05%)

14:05
09/24/18
09/24
14:05
09/24/18
14:05
Options
Viking Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

JNJ

Johnson & Johnson

$140.70

-2.15 (-1.51%)

14:02
09/24/18
09/24
14:02
09/24/18
14:02
Periodicals
Breaking Periodicals news story on Johnson & Johnson »

J&J talc cancer case…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.